Canton Strategic Holdings (CNTN) Research & Development (2021 - 2026)
Canton Strategic Holdings (CNTN) posted Research & Development of $267823.0 for Q1 2026, down 83.83% on a QoQ basis from $1.7 million in Q4 2025, and down 54.92% year-over-year from $594070.0 in Q1 2025.
Canton Strategic Holdings (CNTN) Research & Development (2021 - 2026) Analysis & Trends
Canton Strategic Holdings' Research & Development history runs 6 years deep, the most recent figure standing at $267823.0 for Q1 2026.
- Quarterly Research & Development fell 54.92% year-over-year to $267823.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (down 53.9% YoY) and the FY2025 annual result came in at $3.1 million, down 51.91% from the prior year.
- Research & Development was $267823.0 for Q1 2026 at Canton Strategic Holdings, down from $1.7 million in the prior quarter.
- Across five years, Research & Development topped out at $2.3 million in Q3 2024 and bottomed at $267823.0 in Q1 2026.
- A 5-year average of $915996.6 and a median of $831844.0 in 2022 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development soared 1766.15% — and 2025, when it plunged 87.83%.
- Canton Strategic Holdings' Research & Development stood at $683205.0 in 2022, then surged by 45.3% to $992725.0 in 2023, then soared by 110.07% to $2.1 million in 2024, then retreated by 20.6% to $1.7 million in 2025, then plunged by 83.83% to $267823.0 in 2026.
- Business Quant data shows CNTN's Research & Development at $267823.0 in Q1 2026, $1.7 million in Q4 2025, and $277803.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 541.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -2.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 343.97 Mn |
| 10 | Canton Strategic Holdings | 427.87 Mn | 427.87 Mn | - | 267,823.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 267,823.00 |
| Dec 31, 2025 | 1.66 Mn |
| Sep 30, 2025 | 277,803.00 |
| Jun 30, 2025 | 546,204.00 |
| Mar 31, 2025 | 594,070.00 |
| Dec 31, 2024 | 2.09 Mn |
| Sep 30, 2024 | 2.28 Mn |
| Jun 30, 2024 | 999,553.00 |
| Mar 31, 2024 | 1.03 Mn |
| Dec 31, 2023 | 992,725.00 |
| Sep 30, 2023 | 488,177.00 |
| Jun 30, 2023 | 1.03 Mn |
| Mar 31, 2023 | 1.05 Mn |
| Dec 31, 2022 | 683,205.00 |
| Sep 30, 2022 | 831,844.00 |
| Jun 30, 2022 | 455,546.00 |
| Mar 31, 2022 | 307,829.00 |
| Dec 31, 2021 | -41,005.00 |
| Sep 30, 2021 | 313,133.00 |
| Jun 30, 2021 | 674,765.00 |